Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
Clinical trial NCT00072631 · COMPLETED
Trial details
- NCT number
- NCT00072631
- Sponsor
- OSI Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2003-11-05
- Primary completion
- 2007-03-14
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.